screening-test

A blood test that estimates the chance that a biopsy would find an aggressive prostate cancer, approved by the FDA in December 2021 for men 45 and older with an abnormal PSA or examination.

Abbott's laboratory HPV test, approved by the FDA in November 2023 for primary cervical screening and in 2025 for self-collected samples taken in a clinic.

An HPV test that detects the virus's E6/E7 messenger RNA rather than its DNA, approved by the FDA in 2011, with a follow-on test that names types 16, 18 and 45.

Machines that scan Pap slides and point the human reader to the cells most likely to be abnormal, approved in the United States from 1995 onwards.

BD's laboratory HPV test, approved in 2018, which since 2024 names six high-risk virus types separately, helping decide who needs colposcopy, and accepts samples women take themselves.

BD's liquid-based Pap test, approved in 1999 as AutoCyte PREP and renamed SurePath in 2001.

A stain on cervical cells that helps decide which women with a positive HPV test need colposcopy, approved by the FDA in 2020.

Roche's laboratory test for 14 high-risk HPV types, approved by the FDA for primary cervical screening and, since 2024, for samples women take themselves in a clinic.

Qiagen's hybrid capture HPV test, approved by the FDA in 2003 for use with the Pap test in women 30 and older and for sorting out borderline Pap results.

The first FDA-approved blood test for bowel cancer screening (2016), meant only for people who have been offered and declined the recommended screening tests.

The first FDA-authorised system (January 2024) for reading Pap test slides as digital images with the help of artificial intelligence.

A urine cell test cleared by the FDA in 2000 for monitoring bladder cancer; with ordinary urine cytology it finds more cancers than cytology alone, at the cost of more false positives.

A blood test approved by the FDA in November 2025 to help decide on a prostate biopsy in men 50 and older with a PSA between 4 and 10.

A probe that measures the electrical properties of a worrying mole to give a dermatologist more information before deciding on a biopsy, approved by the FDA in 2017.

A family of stool tests for hidden blood and the laboratory machines that read them, cleared by the FDA from 2010 onwards.

A blood test that combines three forms of PSA into one score, to help men with a moderately raised PSA and a normal examination decide whether to have a biopsy.

The first device the FDA authorised (May 2025) for women to collect their own sample for cervical cancer screening at home, without a clinic visit.

The liquid-based Pap test, approved in 1996, in which cells go into a vial of fluid rather than straight onto a slide; its preservative is the collection medium named in the FDA approvals of several HPV tests.